ABSTRACT
INTRODUCTION Millions of U.S. patients have been hospitalized for COVID-19. After discharge, these patients often have extensive health care needs, but out-of-pocket burden for this care is poorly described. We assessed out-of-pocket spending within 90 days of discharge from COVID-19 hospitalization among privately insured and Medicare Advantage patients.
METHODS In May 2021, we conducted a cross-sectional analysis of the IQVIA PharMetrics® Plus for Academics Database, a national de-identified claims database. Among privately insured and Medicare Advantage patients hospitalized for COVID-19 between March-June 2020, we calculated mean out-of-pocket spending for care within 90 days of discharge. For context, we repeated analyses for patients hospitalized for pneumonia.
RESULTS Among 1,465 COVID-19 patients included, 516 (35.2%) and 949 (64.8%) were covered by private insurance and Medicare Advantage plans. Among these patients, mean (SD) post-discharge out-of-pocket spending was $534 (1,045) and $680 (1,360); spending exceeded $2,000 for 7.0% and 10.3%. Compared with pneumonia patients, mean post-discharge out-of-pocket spending among COVID-19 patients was higher among the privately insured ($534 vs $445) and lower among Medicare Advantage patients ($680 vs $918).
CONCLUSIONS For the privately insured, post-discharge out-of-pocket spending was higher among patients hospitalized for COVID-19 than among patients hospitalized for pneumonia. The opposite was true for Medicare Advantage patients, potentially because insurer cost-sharing waivers for COVID-19 treatment covered the costs of some post-discharge care, such as COVID-19 readmissions. Nonetheless, given the high volume of U.S. COVID-19 hospitalizations to date, our findings suggest a large number of Americans have experienced substantial financial burden for post-discharge care.
INTRODUCTION
Millions of U.S. patients have been hospitalized for coronavirus disease 2019 (COVID-19).1 After discharge, these patients often have extensive health care needs.2-4 However, out-of-pocket burden for this care has been poorly described. Addressing this gap in knowledge is crucial, as substantial out-of-pocket burden for post-discharge care might exacerbate other financial stresses experienced by patients hospitalized for COVID-19, such as loss of employment.4 Using national claims data from privately insured and Medicare Advantage patients, we assessed out-of-pocket spending within 90 days of discharge from COVID-19 hospitalizations during March-June 2020.
METHODS
Study sample
In May 2021, we conducted a cross-sectional analysis of the IQVIA PharMetrics® Plus for Academics Database, which contains medical and pharmacy claims from de-identified patients in all U.S. states. Data included 7.7 million patients covered by fully-insured private plans and 1.0 million patients covered by Medicare Advantage plans in 2020.Claims through September 30, 2020 were available at the time of analysis. Because data were de-identified, the Institutional Review Board of the University of Michigan Medical School exempted analyses from human subjects review.
We identified hospitalizations for privately insured and Medicare Advantage patients that had a primary diagnosis of COVID-19 (ICD-10-CM diagnosis code U071) and that began and ended between March 1-June 30, 2020. We limited analyses to each patient’s first hospitalization during this period. We excluded patients without continuous medical and pharmacy coverage during the 90 days after discharge, patients whose plan was the secondary insurer, and patients with missing out-of-pocket spending data on any claim during the 90 days after discharge.
Measures
We calculated mean out-of-pocket spending (sum of deductibles, co-insurance, and co-payments) across all claims during the 90 days after discharge. Additionally, we calculated mean out-of-pocket spending for 14 service categories: additional hospitalizations, nursing facility admissions, outpatient (e.g., office visits), emergency department visits, radiology, laboratory, diagnostic/therapeutic procedures (e.g., colonoscopy, surgery), physical/occupational/speech/respiratory therapy, home health/hospice, transportation, clinician-administered medications (e.g., infusions), durable medical equipment and supplies, pharmacy-dispensed prescriptions, and miscellaneous (Appendix). For context, we repeated analyses among patients hospitalized for bacterial pneumonia. These patients met similar inclusion and exclusion criterion and did not overlap with the main sample.
Statistical analyses
Within payer types, we compared post-discharge out-of-pocket spending between COVID-19 and pneumonia patients using a one-part generalized linear model with a log link and Poisson variance function, chosen based on the modified Park test.5 Models adjusted for age group, sex, Census region of residence, and month of admission. Analyses used SAS 9.4, Stata 15.1 MP, and two-sided hypothesis tests with α = 0.05.
RESULTS
Of 2,275 COVID-19 patients meeting inclusion criteria, 810 (35.8%) were excluded, leaving 1,465 patients. Table 1 displays sample characteristics. Overall, 516 (35.2%) and 949 (64.8%) patients were covered by private insurance and Medicare Advantage plans.
Characteristics of patients hospitalized for COVID-19 and pneumonia between March-June 2020, IQVIA PharMetrics® Plus for Academics Database
Among privately insured patients, mean (SD) post-discharge out-of-pocket spending was $534 (1,045). For 36 (7.0%) and 15 (2.9%) patients, this spending exceeded $2,000 and $4,000. Service categories accounting for the most out-of-pocket spending were pharmacy-dispensed prescriptions ($130; 24.4% of out-of-pocket spending) and hospitalizations ($111; 20.8%). Among Medicare Advantage patients, mean post-discharge out-of-pocket spending was $680 (1,360). For 98 (10.3%) and 34 (3.6%) patients, this spending exceeded $2,000 and $4,000. Service categories accounting for the most out-of-pocket spending were hospitalizations ($183; 27.0%) and nursing facility admissions ($126; 18.6%) (Table 2). Among privately insured and Medicare Advantage patients, 43.5% and 40.3% of out-of-pocket spending for pharmacy-dispensed prescriptions was for anticoagulants, diabetes drugs (e.g., insulin and sulfonylureas), and bronchodilators. In both populations, these medication classes accounted for the 3 highest shares of out-of-pocket spending for pharmacy-dispensed prescriptions.
Out-of-pocket spending for health care in the 90 days after COVID-19 hospitalization, IQVIA PharMetrics® Plus for Academics Database
Table 1 displays characteristics of the 1,374 patients hospitalized for pneumonia included in analyses. Among the 245 privately insured pneumonia patients, mean (SD) post-discharge out-of-pocket spending was $450 (924), compared with $534 among COVID-19 patients (adjusted difference: -$131, 95% CI: -$135, -$128). Among the 1,129 Medicare Advantage patients, mean (SD) post-discharge out-of-pocket spending was $918 (1,263), compared with $680 among COVID-19 patients (adjusted difference: $291, 95% CI: $288, $294). Among 370 Medicare Advantage patients with additional hospitalizations after a pneumonia hospitalization, 306 (82.7%) had out-of-pocket spending for the additional hospitalizations. Among 206 Medicare Advantage patients with additional hospitalizations after a COVID-19 hospitalization, 141 (68.1%) had out-of-pocket spending for the additional hospitalizations.
DISCUSSION
During the 90 days after COVID-19 hospitalization, privately insured and Medicare Advantage patients paid an average of $534 and $680 for health care; 7.0% and 10.3% of patients paid more than $2,000. For privately insured patients, prescriptions and additional hospitalizations accounted for the highest shares of out-of-pocket spending. For Medicare Advantage patients, additional hospitalizations and nursing facility admissions accounted for the highest shares.
For the privately insured, post-discharge out-of-pocket spending was higher among patients hospitalized for COVID-19 than among patients hospitalized for pneumonia. Perhaps surprisingly, the opposite was true for Medicare Advantage patients. A potential explanation is that some post-discharge care for COVID-19 patients, including readmissions for COVID-19, were covered by insurer cost-sharing waivers for COVID-19 treatment.6 In support of this possibility, Medicare Advantage patients who had additional hospitalizations after a COVID-19 hospitalization were less likely to have out-of-pocket spending for the additional hospitalizations compared with pneumonia patients. As many insurers allowed their cost-sharing waivers to expire in early 20217, post-discharge out-of-pocket spending among patients hospitalized for COVID-19 could now be higher than among study patients.
Even if out-of-pocket spending after COVID-19 hospitalization is not greater than for other conditions, our findings suggest a large number of Americans have experienced substantial post-discharge out-of-pocket spending given the volume of COVID-19 hospitalizations to date. To illustrate this point, national data estimate that 2.25 million COVID-19 hospitalizations occurred between August 1, 2020 and June 13, 2021.1 If 1 in 14 hospitalizations resulted in post-discharge out-of-pocket spending exceeding $2,000 – the rate for privately insured patients in our study – this would translate to roughly 160,000 hospitalizations and more than $320 million billed to patients for post-discharge care. Importantly, the expiration of insurer cost-sharing waivers means that many patients will now be billed for the COVID-19 hospitalization itself, adding further financial burden beyond that associated with post-discharge care. Consequently, monitoring the financial health of patients hospitalized for COVID-19 is a key policy priority going forward.
This study has limitations. First, analyses only captured the immediate period after COVID-19 hospitalization. Second, the post-discharge period in this study occurred during the early stages of the pandemic, when health care utilization decreased sharply owing partly to social distancing measures.8 Post-discharge utilization, and therefore out-of-pocket spending, might be higher now that utilization is rebounding. Third, this study required hospital discharge by June 30, 2020 because a 90-day post-discharge period was needed and claims were complete only through September 30, 2020 at the time of analysis. While necessary, this decision excluded patients with prolonged hospitalizations who may require intensive post-discharge care. Consequently, analyses likely underestimate out-of-pocket burden among all patients hospitalized for COVID-19. Finally, patients may not be fully representative of the entire privately insured and Medicare Advantage population.
CONCLUSIONS
In this national cohort of 1,465 patients hospitalized for COVID-19 during March-June 2020, out-of-pocket spending within 90 days of discharge exceeded $2,000 for 1 in 14 privately insured patients and 1 in 10 Medicare Advantage patients. Future studies should repeat analyses among patients more recently hospitalized for COVID-19 using longer follow-up periods.
Data Availability
Data are proprietary and cannot be shared
Author Contributions
Dr. Chua had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Kao-Ping Chua: Conceptualization, Methodology, Software, Formal analysis, Writing – original draft, Data curation, Writing – review and editing, Visualization, Funding acquisition
Rena Conti: Conceptualization, Methodology, Formal analysis, Writing – review and editing
Nora Becker: Conceptualization, Methodology, Formal analysis, Writing – review and editing, Supervision.
Funding source
Funding for purchasing IQVIA data was partially provided by the Susan B. Meister Child Health Evaluation and Research Center at the University of Michigan Medical School. Dr. Chua’s effort is supported by a career development award from the National Institute on Drug Abuse (grant number 1K08DA048110-01). The funders played no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication
Conflicts of interest
The authors have no conflicts of interest to disclose.
Footnotes
Conflicts of interest: The authors have no conflicts of interest to disclose.
Financial disclosures: none
Title, abstract, and discussion revised slightly
